Prescribing practices of Indian psychiatrists in the treatment of bipolar disorder

Australian and New Zealand Journal of Psychiatry

Volumn 53, Issue 5, 2019, Pages 458-469

  Reddy, YC Janardhan ^a   Jhanwar, Venugopal ^b   Nagpal, Rajesh ^c   Reddy, M S ^d   Shah, Nilesh ^e   Ghorpade, Sanman ^f   Kulkarni, Sujay ^f  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b Department of Psychiatry   (India)

^c Manobal Klinik   (India)

^d Asha Hospital   (India)

^e LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

^f GlaxoSmithKline Pharmaceuticals Ltd   (India)

Author keywords

Bipolar disorder; guidelines; India; prescribing practices

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; FLUOXETINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; NEUROLEPTIC AGENT; TRANQUILIZER;

ACUTE DISEASE; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DEPRESSION; ELECTROCONVULSIVE THERAPY; FACE TO FACE 22 ITEM QUESTIONNAIRE; FEMALE; HEALTH SURVEY; HUMAN; INDIAN; MAINTENANCE THERAPY; MALE; MANIA; MEDICAL LITERATURE; MEDICAL PRACTICE; MONOTHERAPY; PERSONAL EXPERIENCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PROTOCOL COMPLIANCE; PSYCHIATRIST; QUESTIONNAIRE; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; CROSS-SECTIONAL STUDY; INDIA; PSYCHIATRY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HUMANS; INDIA; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PSYCHIATRY; TRANQUILIZING AGENTS;

EID: 85061594818     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867419826718     Document Type: Article

References (51)

1. American Psychiatric Association (APA) (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159: 1–50.
2. Angst J, Sellaro R, (2000) Historical perspectives and natural history of bipolar disorder. Biological Psychiatry 48: 445–457.
3. Bauer MS, (2002) A review of quantitative studies of adherence to mental health clinical practice guidelines. Harvard Review of Psychiatry 10: 138–153.
4. Bauer MS, Biswas K, Kilbourne AM, (2009) Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. American Journal of Psychiatry 166: 1244–1250.
5. Buoli M, Serati M, Altamura AC, (2014) Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. Journal of Affective Disorders 152–154: 12–18.
6. Calabrese JR, Shelton MD, Rapport DJ. (2005) A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry 162: 2152–2161.
7. Calabrese JR, Suppes T, Bowden CL. (2000) A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry 61: 841–850.
8. Geddes JR, Goodwin GM, Rendell J. (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. Lancet 375: 385–395.
9. Ghaemi SN, (2012) Antidepressants in bipolar depression: The clinical debate. Australian and New Zealand Journal of Psychiatry 46: 298–301.
10. Ghaemi SN, Hsu DJ, Thase ME. (2006) Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatric Services 57: 660–665.
11. Gijsman HJ, Geddes JR, Rendell JM. (2004) Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. American Journal of Psychiatry 161: 1537–1547.
12. Goodwin GM, Bowden CL, Calabrese JR. (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry 65: 432–441.
13. Goodwin GM, Haddad PM, Ferrier IN. (2016) Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 30: 495–553.
14. Grunze H, Vieta E, Goodwin GM. (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. The World Journal of Biological Psychiatry 10: 85–116.
15. Grunze H, Vieta E, Goodwin GM. (2010) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. The World Journal of Biological Psychiatry 11: 81–109.
16. Grunze H, Vieta E, Goodwin GM. (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorder. The World Journal of Biological Psychiatry 14: 154–219.
17. Judd LL, Schettler PJ, (2010) The long-term course and clinical management of bipolar I and bipolar II disorders. In: Yatham M, (ed.) Clinical and Neurobiological Foundations, Vol. 1. Oxford: John Wiley & Sons, pp. 17–30.
18. Kemp DE, Gao K, Ganocy SJ. (2009) A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. Journal of Clinical Psychiatry 70: 113–121.
19. Licht RW, Gouliaev G, Vestergaard P. (1997) Generalisability of results from randomised drug trials. A trial on antimanic treatment. British Journal of Psychiatry 170: 264–267.
20. Licht RW, Vestergaard P, Kessing LV. (2003) Psychopharmacological treatment with lithium and antiepileptic drugs: Suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatrica Scandinavica 108: 1–22.
21. Lim PZ, Tunis SL, Edell WS. (2001) Medication prescribing patterns for patients with bipolar I disorder in hospital settings: Adherence to published practice guidelines. Bipolar Disorders 3: 165–173.
22. McElroy SL, Weisler RH, Chang W. (2010) A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry 71: 163–174.
23. Macfadden W, Alphs L, Haskins JT. (2009) A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disorders 11: 827–839.
24. McGirr A, Vöhringer PA, Ghaemi SN. (2016) Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: A systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 3: 1138–1146.
25. Malhi GS, (2012) Bipolar antidepressant agents: Shaken not stirred. Australian and New Zealand Journal of Psychiatry 46: 289–292.
26. Malhi GS, (2015) Antidepressants in bipolar depression: Yes, no, maybe? Evidence Based Medical Health 18: 100–102.
27. Malhi GS, Adams D, Lampe L. (2009) Clinical practice recommendations for bipolar disorder. Acta Psychiatica Scaninavica 439: 27–46.
28. Malhi GS, Bargh DM, McIntyre R. (2012) Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disorders 14: 1–21.
29. Malhi GS, Bassett D, Boyce P. (2015a) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry 49: 1087–1206.
30. Malhi GS, Masson M, Bellivier F, (2015b) Teasing apart bipolar III: The causes and consequences of a treatment-emergent affective switch (TEAS) into mania. Australian and New Zealand Journal of Psychiatry 49: 866–868.
31. Malhi GS, Outhred T, Das P. (2018a) Modeling suicide in bipolar disorders. Bipolar Disorders 20: 334–348.
32. Malhi GS, Porter R, Irwin L. (2018b) Defining a mood stabiliser: Novel framework for research and clinical practice. BJPsych Open 4: 278–281.
33. Morriss R, (2008) Implementing clinical guidelines for bipolar disorder. Psychology and Psychotherapy 81: 437–458.
34. National Institute for Health Clinical Excellence (NICE) (2014) Bipolar Disorder (Update): The Management of Bipolar Disorder in Adults, Children and Adolescents in Primary and Secondary Care (Clinical Guideline CG185). London: NICE. Available at: https://www.nice.org.uk/guidance/cg185
35. Nolen WA, Kupka RW, Schulte PFJ. (2008) Richtlijn bipolaire stoornissen, 2nd Edition. Utrechtl: De Tijdstrom Uitgerverij B.V.
36. Novick DM, Swartz HA, Frank E, (2010) Suicide attempts in bipolar I and bipolar II disorder: A review and meta-analysis of the evidence. Bipolar Disorders 12: 1–9.
37. Ogawa Y, Tajika A, Takeshima N. (2014) Mood stabilizers and antipsychotics for acute mania: A systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 28: 989–1003.
38. Pacchiarotti I, Bond DJ, Baldessarini RJ. (2013) The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry 170: 1249–1262.
39. Perlis RH, (2007) Use of treatment guidelines in clinical decision making in bipolar disorder: A pilot survey of clinicians. Current Medical Research and Opinion 23: 467–475.
40. Perugi G, Fornaro M, (2011) Bipolar disorder treatment guidelines and their limits in every day clinical practice. Giornale Italiano di Psicopatologica 17: 261–264.
41. Sachs GS, Nierenberg AA, Calabrese JR. (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine 356(17): 1711–1722.
42. Samalin L, Guillaume S, Auclair C. (2011) Adherence to guidelines by French psychiatrists in their real world of clinical practice. The Journal of Nervous and Mental Disease 199: 239–243.
43. Shah N, Grover S, Rao GP, (2017) Clinical practice guidelines for management of bipolar disorder. Indian Journal of Psychiatry 59: S51–S66.
44. Sidor MM, MacQueen GM, (2011) Antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Journal of Clinical Psychiatry 72: 156–167.
45. Smith TE, Levine SB, Hampel J, (2008) A successful effort to improve adherence to treatment guidelines for bipolar disorder. Harvard Review of Psychiatry 16: 210–213.
46. Thirthalli J, Prasad MK, Gangadhar BN, (2012) Electroconvulsive therapy (ECT) in bipolar disorder: A narrative review of literature. Asian Journal of Psychiatry 5: 11–17.
47. Tondo L, Hennen J, Baldessarini RJ, (2003) Rapid-cycling bipolar disorder: Effects of long-term treatments. Acta Psychiatrica Scandinavica 108: 4–14.
48. Versiani M, Cheniaux E, Landeira-Fernandez J, (2011) Efficacy and safety of electroconvulsive therapy in the treatment of bipolar disorder: A systematic review. The Journal of ECT 27: 153–164.
49. Vieta E, Morralla E, (2007) P.2.e.017 bipolar disorder treatment guidelines followed by Spanish psychiatrists. GAMEB study. European Neuropsychopharmacology 17: S385–S386.
50. Yatham LN, Kennedy SH, O’Donovan C. (2005) Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disorders 7: 5–69.
51. Yatham LN, Kennedy SH, Parikh SV. (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders 20: 97–170.